Carboplatin + Pemetrexed + Atezolizumab for Lung Cancer

Recruiting in Palo Alto (17 mi)

Overseen by Liza C. Villaruz

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Liza Villaruz, MD

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients with asymptomatic untreated brain metastases.

Eligibility Criteria

This trial is for adults with non-squamous NSCLC and untreated brain metastases. Participants must have normal organ function, no recent severe infections or surgeries, and not be on systemic immunosuppressants. They should agree to contraception if of childbearing potential and can't join if they've had certain treatments for metastatic disease or have specific viral infections.

Inclusion Criteria

I have had radiation for cancer spread outside the brain with the goal of easing symptoms.

My blood counts and liver/kidney functions are within normal ranges.

I do not have active hepatitis B or am not on treatment for it.

Exclusion Criteria

I haven't had major surgery in the last 4 weeks and don't expect to need one during the study.

I have had lung issues like fibrosis or pneumonia, but not from radiation.

I don't have any health issues that would make it unsafe for me to take a new drug.

Participant Groups

The study tests the combination of tiragolumab with carboplatin, pemetrexed, and atezolizumab in treating metastatic non-squamous NSCLC patients who also have asymptomatic brain metastases. It aims to assess safety and how well this combination works as a first-line treatment.

Group I: Single Treatment Arm Experimental Treatment 4 Interventions

Tiragolumab in combination with atezolizumab, pemetrexed, and carboplatin.

Atezolizumab is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

🇪🇺 Approved in European Union as Tecentriq for:

• Melanoma
• Hepatocellular carcinoma
• Small cell lung cancer
• Non-small cell lung cancer
• Urothelial carcinoma

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

UPMC Hillman Cancer Center Pittsburgh, PA

Who Is Running the Clinical Trial?

Liza Villaruz, MD Lead Sponsor

Genentech, Inc. Industry Sponsor

References